News | July 03, 2023
Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
The company is already marketing the 4 mg and 10 mg strengths
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
The company will supply materials to all global regions including Asia such as China, India, Europe, and the U.S.
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
Subscribe To Our Newsletter & Stay Updated
